SAFETY DATA SHEET PRODUCT ID: LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION SECTION 1: PRODUCT AND COMPANY IDENTIFICATION
Lidocaine hydrochloride 2% and Epinephrine 1:50,000 Injection
Lidocaine hydrochloride 2% and Epinephrine 1:100,000 Injection
OCTOCAINE® 50 (Lidocaine Hydrochloride 2% and Epinephrine 1:50, 000 Injection) LIGNOSPAN® FORTE (Lidocaine Hydrochloride 2% and Epinephrine 1:50, 000 Injection) OCTOCAINE® 100 (Lidocaine Hydrochloride 2% and Epinephrine 1:100, 000 Injection) LIGNOSPAN ® STANDARD (Lidocaine Hydrochloride 2% and Epinephrine 1:100, 000 Injection)
Novocol Pharmaceutical of Canada, Inc. P. O. Box 68 Cambridge, Ontario, Canada N1R 5S9 519-623-4800
Novocol Pharmaceutical in conjunction with a third party consultant
1-519-623-4800 (Monday-Friday 08:30 to 16:30)
Local anesthetic solution for use in peripheral nerve blocks
SECTION 2: HAZARDS IDENTIFICATION
H336 - May cause drowsiness or dizziness
Causes central nervous system effects such as drowsiness, confusion, excitability and nervousness. Acts as a depressant on the cardiovascular system.
Avoid use in individuals with hypersensitivities to amide-type anesthetics. Use with caution in individuals with diabetes and/or severe hypertension.
CONSULT PRODUCT INSERT FOR CLINICAL AND PHARMACOPIAL INFORMATION
Signs and Symptoms of Overexposure: Drowsiness, confusion, excitability, nervousness, drop in blood pressure, fatigue, bluish discoloration of fingernails, lips, or skin, difficulties in breathing.
SAFETY DATA SHEET PRODUCT ID: LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION Prevention P261 – Do not breathe mist/vapours/spray P271 – Use in a well-ventilated area Response P304+P430 – If inhaled – remove victim to fresh air and keep at rest in a position comfortable for breathing P312 – Call a POISON CENTER or doctor/physician if you feel unwell Storage P405 – Store locked up Disposal P501 – Dispose of contents/container in accordance with local/provincial/federal regulations SECTION 3: COMPOSITION / INFORMATION ON INGREDIENTS Chemical Identity Concentration CAS Number (Percent weight/weight) SECTION 4: FIRST AID MEASURES
Flush eyes with plenty of water for at least 15 minutes while holding eyelids open. Get medical attention, if irritation persists.
Remove contaminated clothing. Wash skin with soap and water
Get immediate medical attention. Do not induce vomiting unless instructed to do so by poison control or physician.
Wear impermeable gloves to avoid skin contact (e.g. nitrile, natural
SECTION 5: FIRE FIGHTING MEASURES
Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials
As with all fires, evacuate personnel to a safe area. Firefighters should
use self-contained breathing equipment and protective clothing.
SAFETY DATA SHEET PRODUCT ID: LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION SECTION 6: ACCIDENTAL RELEASE MEASURES
Caution should be used to prevent against ingestion and contact with eyes. Wear safety glasses with side shields.
Prevent spills from entering sewers and watercourses. Cover drains.
Clean up spills with normal procedures used for non-hazardous
liquids. This can include: absorb spill with inert material, then place in a chemical waste container. Clean surface thoroughly with water to remove residual contamination.
SECTION 7: HANDLING AND STORAGE
Caution should be used to prevent against ingestion and contact with eyes.
Store in a cool, dry place. Avoid extremes in temperature.
USP Type 1 glass with rubber stopper and cap
SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION Occupational Exposure Limits (OEL) Chemical ACGIHa Ontario TWAb STELc TWAb STELc
a – American Conference of Governmental Industrial Hygienists b – Time Weighted Average c - Short-term Exposure Limit
RESUSCITATIVE EQUIPMENT AND DRUGS SHOULD BE AVAILABLE DURING DENTAL PROCEDURES
SAFETY DATA SHEET PRODUCT ID: LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES SECTION 10: STABILITY AND REACTIVITY
Incompatible with compounds which react violently with water
SECTION 11: TOXICOLOGICAL INFORMATION
Acute measures of toxicity (i.e. LD50 and LC50) are not available for this mixture.
SAFETY DATA SHEET PRODUCT ID: LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION
LD50 for Lidocaine Hydrochloride: 317 mg/kg oral rat
LD50 for Epinephrine: 5 mg/kg dermal rat
This product has not been listed as a carcinogen or a potential carcinogen by the ACGIH, the International Agency for Research on Cancer (IARC), the US National Toxicology Program (NTP) or the US Occupational Safety and Health Administration (OSHA).
No significant effects were observed on fetal development. However, animal studies have found that continuous exposure throughout pregnancy may decrease birth weight.
Specific Target Organ Toxicity – Single
May cause hypersensitivity. Associated with the development of
Not available. Not expected to be of concern.
SECTION 12: ECOLOGICAL INFORMATION SECTION 13: DISPOSAL CONSIDERATIONS
Observe all Federal/Provincial/State and Local disposal regulations.
SECTION 14: TRANSPORTATION INFORMATION SAFETY DATA SHEET PRODUCT ID: LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION
Avoid temperature extremes. Prevent from freezing.
SECTION 15: REGULATORY INFORMATION
This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations and the MSDS contains all the information required by the Controlled Products Regulations.
Epinephrine is listed as a hazardous product in the RCRA (EPA) and CERCLA (EPA) regulations.
This product is exempt from WHMIS as a drug product
SECTION 16: OTHER INFORMATION
Novocol Pharmaceutical in conjunction with a third party consultant
Information and statements contained in this document have been obtained from manufacturers, suppliers and recognized reference sources as provided to or obtained by Novocol Pharmaceutical of Canada, Inc. Novocol Pharmaceutical of Canada, Inc. believes the information to be reliable but expressly disclaims any liability for providing such information and toxicology to our customers.
Physical Therapy in Sport 5 (2004) 2–12Myofascial trigger points: the current evidenceCentre for Sports Medicine Research and Education, University of Melbourne, 300 Berkeley Street, Parkville, Vic., AustraliaReceived 10 November 2003; revised 17 November 2003; accepted 18 November 2003This paper provides an overview of the current state of knowledge regarding the history, pathophysiol
This fact sheet has been produced by the Female Urology Special Advisory Group (SAG) of the Urological Society of Australia and New Zealand Interstitial cystitis or Painful Bladder Syndrome Painful bladder conditions are common and interstitial cystitis (IC) is one of the causes. People with IC suffer pain when the bladder is full and/or have to urinate frequently. The cause is unkno
SAFETY DATA SHEET